ChemicalBook Product Catalog Biochemical Engineering Nucleoside drugs Nucleoside Intermediates NECA

NECA

Product NameNECA
CAS35920-39-9
MFC12H16N6O4
MW308.29
EINECS
MOL File35920-39-9.mol

Chemical Properties

Melting point	229-231°C
Density	1.87±0.1 g/cm3(Predicted)
storage temp.	2-8°C
solubility	45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.2 mg/mL Solutions may be stored for several days at 4°C.
pka	12.93±0.70(Predicted)
form	powder
color	white
Water Solubility	45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.2mg/mL (Solutions may be stored for several days at 4 °C.) DMSO: 14mg/mL (Solutions may be stored for several days at 4 °C.) 0.1 M HCl: 3.4mg/mL (Solutions may be stored for several days at 4 °C.) H2O: insoluble ethanol: soluble (Solutions may be stored for several days at 4 °C.)
Stability	Hygroscopic
InChIKey	JADDQZYHOWSFJD-FLNNQWSLSA-N
CAS DataBase Reference	35920-39-9

Safety Information

Hazard Codes	T+
Risk Statements	28
Safety Statements	22-26-36-45
RIDADR	UN 2811 6.1/PG 2
WGK Germany	3
RTECS	VJ2232000
HazardClass	6.1(a)
PackingGroup	I
HS Code	29349990

MSDS

Provider	Language
SigmaAldrich	English

Usage And Synthesis

Chemical Properties

White Solid

Uses

5′-(N-Ethylcarboxamido)adenosine has been used:

for the purification of human adenosine A_2Areceptor (A_2AR) in decylmaltoside (DM)
to determine nonspecific binding of adenosine receptors
to investigate adenosine 2B receptor (RA2B) mechanism of action by competition assay

Uses

Potent adenosine receptor agonist with some affinity at A1 and A2 receptors

Uses

A potent adenosine receptor agonist. Inhibits platelet aggregation and is centrally active in vivo

Definition

ChEBI: A derivative of adenosine in which the 5'-hydroxymethyl group is replaced by an N-ethylcarboxamido group.

General Description

A cell-permeable adenosine analog that acts a potent non-selective agonist of adenosine receptors (K_i = 14 nM, 20 nM, 2.4 μM and 6.2 nM for A₁, A_2A, A_2B, A₃, respectively). Increases intracellular cAMP production (EC₅₀ = 3.1 μM in A_2B expressing CHO cells). Shown to increase glucagon release in a dose-dependent manner and inhibit insulin release at low concentrations. Although at higher concentration some insulin release is observed. Also, displays a wide range adenosine-dependent effects, such as blocking platelet aggregation and inhibiting DNA synthesis. When administered at reperfusion, it is shown reduce infarction and block the formation of the mitochondrial permeability transition pore by activating p70S6 kinase.

Biological Activity

Potent adenosine receptor agonist (K i values are 14, 20 and 6.2 nM for human A 1 , A 2A and A 3 receptors respectively; EC 50 = 2.4 μ M for human A 2B ). Inhibits platelet aggregation and is centrally active in vivo .

Biochem/physiol Actions

Reversible: yes

storage

Store at +4°C

NECA Supplier

NECA manufacturers

Related Product Information

Send Inquriy